ACTRN12623000530628已完成1 期
A single dose, randomized, double-blind, bioavailability pilot study of a test formulation of iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet in a 2 way crossover comparison against the innovator iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet conducted in iron deficient participants under fed conditions with diet control.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Participants with a ferritin result <30ug/L
- •Aged between 18 and 55
- •Non-smoker
- •BMI between 18.5 and 32.0 inclusive
- •Able to consume a low-iron diet for a period of 16 days.
- •Females who are within 2 days of their menstruation or on hormonal contraceptives and able to control the timing of their menstrual cycle throughout the study.
- •Healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
- •Able to provide written informed consent
排除标准
- •Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
- •Any history of iron-overload
- •Concomitant drug therapy of any kind
- •Sensitivity to iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide or any other similar class of medicines, or any excipients in either formulation.
- •History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Smoker (anyone who has smoked in the last 6 months)
- •History of alcohol or drug abuse or dependency
- •Participation in a drug study within 30 days of the start of the study or donated blood in the 30 days preceding the study.
- •Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk
研究者
相似试验
已完成
1 期
Comparative assessment of the absorption of an Iron Polymaltose tablet against an innovator product conducted in iron deficient participants under fed conditions with diet control (low iron and low fat).Iron DificiencyDiet and Nutrition - Other diet and nutrition disordersBlood - AnaemiaACTRN12623001001684Zenith Technology Corporation Limited24
进行中（未招募）
不适用
A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram per actuation administered by means of a spacer device (AeroChamber Plus) with that of Formoterol-HFA pMDI 12 microgram per actuation in 5- to 12-year-old children with persistent moderate to severe asthmaPersistent moderate to severe childhood asthma (5 to 12 years of age, inclusive)MedDRA version: 8.1Level: PTClassification code 10049585EUCTR2006-000907-41-HUChiesi Farmaceutici S.p.A.42
进行中（未招募）
1 期
A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 µg NEXThaler® versus CHF1535 100/6 µg pMDI in asthmatic patients.MedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-003672-47-GBChiesi Farmaceutici S.p.A.60
已完成
1 期
Comparative assessment of the absorption of a generic formulation of iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet against the innovator iron(3+);(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;trihydroxide tablet conducted under fasting conditions with diet control in healthy male volunteersIron deficiencyBlood - AnaemiaDiet and Nutrition - Other diet and nutrition disordersACTRN12620001227987Zenith Technology Corporation Limited24
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100 µg/actuation (Ventolin Evohaler) therapy in asthmatic patients. - MART 1 Maintenance And Reliever TherapyAshtmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2008-000905-12-ITCHIESI